Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyBlue Cross Blue Shield NE Cardiovascular Prior Aut…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentBlue Cross Blue Shield - NebraskaPolicy M.88

    MA Specialty Testing: Cardiovascular (Preauthorization Required)

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Nebraska Policy M.88 alerts

    Get alerted when Policy M.88 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Policy M.88 governs preauthorization, medical necessity criteria, and coverage for genetic and specialty cardiovascular tests (multigene panels and related testing) for inherited and sporadic cardiomyopathies, arrhythmias, aneurysm syndromes, and related conditions; it applies to Blue Cross Blue Shield - Nebraska members and providers requesting testing.

    Policy Summary
    PayerBlue Cross Blue Shield - Nebraska
    PolicyMA Specialty Testing: Cardiovascular (Preauthorization Required)
    Policy CodePolicy M.88
    Change TypeNo material changes
    Effective DateMay 1, 2026
    Next Review DateJan 1, 202743d
    Key ActionObtain preauthorization and submit documentation showing the member meets condition-specific clinical criteria before requesting cardiovascular genetic testing.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    multigene panelstests
    preauthorization requiredauthorization
    05-01-2026effective
    01-01-2027next review
    15 mmHCM threshold
    EF <50%DCM threshold

    Coverage Criteria for Cardiovascular Genetic and Specialty Testing

    Comprehensive Cardiomyopathy Panels

    Covered when ANY of the following are met

    Comprehensive cardiomyopathy panels criteria: A. The member has a diagnosis of cardiomyopathy; OR B. The member has a first-degree relative with sudden cardiac death (SCD) or sudden unexplained death (SUD) AND either (1) the relative's autopsy revealed unspecified cardiomyopathy (e.g., cardiomegaly or cardiomyopathy) OR (2) the relative's autopsy revealed an anatomically normal heart and the autopsy did not reveal a cause of death.

    Multigene panels should be targeted to the observed cardiomyopathy phenotype; panels are not reasonable and necessary for other indications.

    Comprehensive Arrhythmia Panels

    Covered when ANY of the following are met

    Comprehensive arrhythmia panels criteria: Member meets one of: (1) a first-degree relative with SCD or SUD before age 50; OR (2) a first-degree relative with SCD at age ≥50 AND (a) the deceased had family history of premature SCD OR (b) the death was suspicious for genetic heart disease; OR (3) the member has unexplained sudden cardiac arrest AND clinical tests (ECG, stress testing, echocardiogram, intravenous pharmacologic provocation testing) were non-diagnostic for reversible, ischemic, or structural causes.
    Policy Summary
    PayerBlue Cross Blue Shield - Nebraska
    PolicyMA Specialty Testing: Cardiovascular (Preauthorization Required)
    Policy CodePolicy M.88
    Change TypeNo material changes
    Effective DateMay 1, 2026
    Next Review DateJan 1, 202743d
    Key ActionObtain preauthorization and submit documentation showing the member meets condition-specific clinical criteria before requesting cardiovascular genetic testing.
    SourceLink
    On This Page
    Coverage Criteria for Cardiovascular Genetic and Specialty TestingProvider Actions, Authorization, and Documentation RequirementsCPT, CPT-PLA, and Molecular Pathology CodesBackground and ScopeKey Definitions and Panel Content RequirementsPolicy Revision History

    Panels not reasonable and necessary for other indications.

    Comprehensive Arrhythmia and Cardiomyopathy Panels (SUD/SCD)

    Covered when ALL of the following are met

    Comprehensive arrhythmia and cardiomyopathy panels: A. Member meets clinical criteria for Comprehensive Cardiomyopathy Panels; AND B. Member meets clinical criteria for Comprehensive Arrhythmia Panels.

    Combined panels are not reasonable and necessary for other indications.

    Hypertrophic Cardiomyopathy Panels

    Covered when ANY of the following are met

    HCM multigene panel criteria: Member has unexplained left ventricular hypertrophy (LVH) defined by maximal myocardial wall thickness ≥15 mm in adults OR z-score ≥2 in children on echocardiogram or cardiac MRI.LV wall thickness ≥15 mm (adults); z-score ≥2 (children)

    Panels not reasonable and necessary for other indications; if a panel is performed use the appropriate panel code.

    Dilated Cardiomyopathy Panels

    Covered when ALL of the following are met

    DCM multigene panel criteria: A. Findings characteristic of dilated cardiomyopathy including: (1) left ventricular enlargement on echocardiogram or cardiac MRI; AND (2) systolic dysfunction (e.g., ejection fraction <50%) on imaging or left ventricular angiogram; AND (3) non-genetic causes of DCM have been ruled out (prior myocardial infarction, valvular or congenital disease, toxins, thyroid disease, inflammatory/infectious conditions, severe long-standing hypertension, radiation).Ejection fraction <50%

    Panels not reasonable and necessary for other indications; if a panel is performed use the appropriate panel code.

    Hypertrophic Cardiomyopathy - Initial Testing

    HCM: Covered when ANY of the following are met

    HCM initial testing: Member has unexplained left ventricular hypertrophy defined by myocardial wall thickness ≥15 mm in adults OR z-score ≥2 in children on echocardiogram or cardiac MRI.wall thickness ≥15 mm (adults); z-score ≥2 (children)

    If a panel is performed, use appropriate panel code; panels not reasonable and necessary for other indications.

    Dilated Cardiomyopathy - Initial Testing

    DCM: Covered when ALL of the following are met

    DCM initial testing: 1) Left ventricular enlargement based on echocardiogram or cardiac MRI; AND 2) Systolic dysfunction (e.g., ejection fraction <50%) on imaging or left ventricular angiogram; AND 3) Non-genetic causes of DCM have been excluded (prior MI, valvular/congenital heart disease, toxins, thyroid disease, inflammatory/infectious conditions, severe chronic hypertension, radiation).EF <50%

    If a panel is performed, use appropriate panel code; panels not reasonable and necessary for other indications.

    Arrhythmogenic Cardiomyopathy - Initial Testing

    Arrhythmogenic (ARVC): Covered when EITHER one major criterion OR two minor criteria from Task Force are met

    ARVC major criterion: Member has any single major diagnostic Task Force criterion from imaging (echo/MRI/angiography), endomyocardial biopsy, ECG, or family history as specified (examples: regional RV akinesia/dyskinesia/aneurysm with quantitative cutoffs; pathologic fibrous replacement on biopsy; ECG epsilon waves or inverted T waves in right precordial leads in individuals >14 years; ARVC confirmed in a first-degree relative).Various modality-specific numeric thresholds per policy (e.g., PLAX RVOT >32 mm; RVEF <40%; Rao RVEDV/BSA >110 mL/m2 male, >100 mL/m2 female)

    See Task Force criteria sections for detailed imaging, ECG, biopsy, Holter and family history thresholds.

    ARVC two minor criteria: Member has any two of the listed minor Task Force criteria across imaging, MRI, biopsy, ECG, Holter, or family history sections with specified ranges/values (examples: PLAX RVOT 29–32 mm; PSAX RVOT 32–36 mm; fractional area change 33–40%; RVEF 40–45%; late potentials by SAECG parameters; >500 ventricular extrasystoles per 24 hours).Ranges per modality as specified in policy

    If a panel is performed, use the appropriate panel code; panels not reasonable and necessary for other indications.

    Restrictive Cardiomyopathy - Not Covered

    Restrictive Cardiomyopathy (RCM):

    RCM not covered: Genetic testing for restrictive cardiomyopathy via multigene panel is considered not reasonable and necessary for all indications in this policy excerpt.

    No covered indications listed in this excerpt.

    Long QT Syndrome - Initial Testing

    Covered when EITHER A or B diagnostic/symptomatic conditions are met, AND non-genetic causes are excluded

    LQTS asymptomatic: Asymptomatic member AND (confirmed prolonged QTc on resting ECG or provocative testing: >460 ms prepuberty or >480 ms adults) OR a close relative with clinical LQTS whose genetic status is unknown.QTc >460 ms (prepuberty); >480 ms (adults)

    Non-genetic causes of prolonged QTc (eg, QT-prolonging drugs, electrolyte abnormalities, structural heart disease) must be ruled out.

    LQTS symptomatic: Symptomatic member (eg, syncope, cardiac arrest) AND (cardiologist has strong clinical suspicion based on history/family/ECG phenotype OR Schwartz score ≥3.0) AND non-genetic causes of prolonged QTc have been excluded.Schwartz score ≥3.0

    If a pathogenic variant is known in an affected family member, follow familial variant analysis criteria.

    Short QT Syndrome - Initial Testing

    Covered when ANY of the following are met

    SQTS QTc: Member has a QTc ≤330 ms on ECG.QTc ≤330 ms

    If a panel is performed, use appropriate panel code.

    SQTS score: Member has an SQTS diagnostic score ≥4 based on the ECG, clinical history, family history, and genotype point system.SQTS score ≥4

    High-probability SQTS per diagnostic scoring; cascade testing recommended when a pathogenic variant is identified.

    SQTS familial: Asymptomatic member with a first-degree relative with clinical SQTS whose genetic status is unknown.

    If a pathogenic variant is known in an affected family member, follow familial variant analysis criteria.

    Brugada Syndrome - SCN5A single-gene covered; other gene testing not covered

    Covered when ALL of the following are met for SCN5A analysis

    Brugada SCN5A criteria: A) Member meets Brugada ECG criteria (Type 1 EKG, or Type 2/3 with conversion to Type 1 after sodium channel blocker challenge); AND B) Phenocopies (eg, myocardial ischemia, electrolyte disturbances, drug intoxications) have been ruled out; AND C) Member has at least one clinical feature such as recurrent syncope, ventricular fibrillation, polymorphic VT, cardiac arrest, or family history of sudden cardiac death.ECG morphology definitions per policy

    SCN5A single-gene testing acceptable when criteria met; genetic testing of other Brugada genes or panels is considered not reasonable and necessary.

    Brugada other genes not covered: Genetic testing for Brugada via genes other than SCN5A, including multigene panels, is considered not reasonable and necessary for indications not meeting the specified criteria.

    Reporting of genes with disputed ClinGen validity is discouraged in diagnostic setting.

    CPVT - Initial Testing

    Covered when ALL of the following are met

    CPVT criteria: A) No known structural cardiac abnormalities; AND B) The member has any of: exertional or emotion-related syncope; exercise- or emotion-related palpitations/dizziness; sudden unexpected cardiac death triggered by exertion/emotion; family history of juvenile SCD triggered by exertion/emotion; exercise-induced bidirectional or polymorphic ventricular arrhythmias; or ventricular fibrillation occurring with acute stress.

    If a panel is performed, use appropriate panel code; panels not reasonable and necessary for other indications.

    Familial Hypercholesterolemia - Initial Testing

    Covered when ALL of the following are met

    FH criteria: A) Member has at least two or more elevated LDL-C measurements including assessment after intensive lifestyle modification; AND B) No apparent secondary cause of hypercholesterolemia; AND C) Age-specific LDL-C thresholds and family/personal history criteria are met (examples: child LDL-C ≥190 mg/dL; child LDL-C ≥160 mg/dL with affected first-degree relative or premature CAD; adult LDL-C ≥250 mg/dL; adult LDL-C ≥190 mg/dL with affected first-degree relative or premature CAD; adult LDL-C ≥160 mg/dL with family history or personal history of premature CAD).LDL-C thresholds per age and context

    Testing should include at minimum LDLR, APOB, and PCSK9; expanded panels may be considered for phenocopy conditions; cascade testing recommended when pathogenic variant found.

    TAAD - Initial Testing

    Covered when ALL of the following are met

    TAAD multigene panel criteria: A) Member has history of aortic root enlargement OR thoracic aneurysm OR type A or B aortic dissection; AND B) Member does not otherwise meet diagnostic criteria for another connective tissue disorder; AND C) Member has a family history of dilation or dissection of the aortic root consistent with autosomal dominant inheritance.

    A multigene panel comprising HTAD genes is recommended; panels not reasonable and necessary for other indications.

    HHT - Initial Testing

    Covered when ALL of the following are met

    HHT multigene panel criteria: A) Member has any of the following clinical features: spontaneous recurrent epistaxis; OR mucocutaneous telangiectases at characteristic sites; OR visceral arteriovenous malformation (pulmonary, cerebral, spinal, gastrointestinal or pancreatic); AND B) The panel includes at minimum ACVRL1 and ENG genes.

    Diagnostic genetic testing is recommended in symptomatic individuals to establish molecular diagnosis and enable cascade testing; panels not reasonable and necessary for other indications.

    Congenital Heart Malformations - Initial Testing

    Covered when ALL of the following are met

    Congenital heart malformation criteria: A) Member has a complex congenital heart malformation (eg, hypoplastic left heart, transposition of the great vessels, tetralogy of Fallot); AND B) Clinical features do not fit a known genetic disorder for which targeted testing could be performed (eg, 22q11.2 deletion, Down syndrome, Williams syndrome); AND C) Prenatal teratogen exposure has been considered and ruled out when possible.

    Multigene panel testing not reasonable and necessary for simple congenital defects; use targeted testing when a specific syndrome is suspected.

    Phenotype-directed panel coverage

    Covered when guideline-based, phenotype-directed criteria are met as described by specialty society recommendations

    Phenotype-directed panel coverage - summary

    • HCM guidance: HCM diagnosed by imaging (adults: maximal end-diastolic LV wall thickness >15 mm) — genetic testing is recommended to identify at-risk relatives and guide management.>15 mm

      See professional society guidance.

    • DCM guidance: DCM defined by LV dilatation and systolic dysfunction (eg, EF <50%) — genetic testing is useful and recommended, particularly when yield is highest.EF <50%

      See HFSA and cardiomyopathy guidance.

    • Arrhythmia guidance: For survivors of sudden cardiac arrest, SUD victims, and relatives, multidisciplinary evaluation and phenotype-directed genetic testing is recommended; autopsy tissue suitable for DNA should be collected when available; hypothesis-free exome/genome testing without phenotype is discouraged.phenotype present

      See EHRA/HRS/APHRS consensus.

    Short QT Syndrome - Recommended testing

    SQTS testing — recommended when ANY of the following guideline-derived conditions are met

    SQTS recommended testing indications: Molecular genetic testing for definitive SQTS genes (eg, KCNH2, KCNQ1) is recommended in index patients who satisfy diagnostic criteria for SQTS (eg, Class I clinical diagnosis or SQTS diagnostic score ≥4). Testing of KCNJ2 and SLC4A3 may be performed in high-probability cases; cascade testing is recommended when a pathogenic variant is identified.SQTS diagnostic score ≥4

    ECG and clinical documentation should support diagnosis; use appropriate panel code.

    Brugada Syndrome - Recommended testing

    Brugada syndrome — recommended when ALL of the following are present

    Brugada recommended testing requirements: Clinical suspicion (recurrent syncope, ventricular fibrillation, polymorphic VT, cardiac arrest, or family history of sudden cardiac death) AND a compatible ECG pattern (Type 1 or Type 2/3 with conversion to Type 1 after sodium channel blocker challenge) AND exclusion of phenocopies (eg, ischemia, electrolyte disturbance, drugs).EKG Type 1 or inducible Type 1

    SCN5A is the primary gene with strong gene–disease validity; reporting of other disputed genes for diagnostic purposes is discouraged.

    Catecholaminergic Polymorphic Ventricular Tachycardia - Recommended testing

    CPVT — recommended when ALL of the following are met

    CPVT recommended testing criteria: Presence of exercise- or emotion-induced bidirectional or polymorphic VT in a structurally normal heart with normal resting ECG, or clinical features such as exertional syncope or family history of juvenile sudden cardiac death triggered by exercise/emotion; when criteria are met, molecular genetic testing is recommended.Clinical criteria per GeneReviews/HRS consensus

    Refer to HRS/EHRA/APHRS 2013 and more recent consensus statements for specific diagnostic thresholds.

    Familial Hypercholesterolemia - Recommended testing

    Familial hypercholesterolemia (FH) testing — recommended when ANY of the following are met

    FH recommended testing indications: Offer genetic testing to individuals with a strong clinical index of suspicion for FH: children with persistent LDL‑C >160 mg/dL (or ≥190 mg/dL in more severe scenarios) or adults with persistent LDL‑C >190 mg/dL (or ≥250 mg/dL) without secondary causes; testing should include analysis of LDLR, APOB, and PCSK9 at minimum, with expanded panels considered for phenocopies; cascade testing recommended when pathogenic variant found.LDL-C thresholds per age/context

    Two or more LDL-C measurements including assessment after intensive lifestyle modification are recommended before testing.

    TAAD - Recommended testing

    Heritable thoracic aortic disease (HTAD) — recommended when ALL of the following apply

    TAAD recommended testing indications: Patients with aortic root/ascending aortic aneurysm or aortic dissection and risk factors for hereditary thoracic aortic disease (eg, syndromic features, presentation <60 years, family history of TAD or peripheral/intracranial aneurysms, unexplained early sudden death) should be offered multigene panel testing including HTAD-associated genes.Presence of described risk factors

    Multigene panel comprising suspected HTAD genes is recommended as the most cost-effective and clinically useful approach.

    Hereditary Hemorrhagic Telangiectasia - Recommended testing

    Hereditary hemorrhagic telangiectasia (HHT) — recommended when ANY of the clinical Curaçao criteria are met

    HHT recommended testing indications: Diagnostic genetic testing is recommended for symptomatic individuals with features suggestive of HHT (recurrent spontaneous epistaxis, multiple characteristic telangiectases, visceral AVMs, or a first-degree relative meeting Curaçao criteria) to establish a molecular diagnosis and enable cascade testing; panels should include ACVRL1 and ENG at minimum and may include SMAD4.Curaçao criteria (≥3 features) or suggestive findings

    Use appropriate panel code and document clinical findings to support testing.

    Each cardiomyopathy section of this policy specifies that multigene panels are covered only for the listed clinical indications and that multigene panels are considered not reasonable and necessary for all other indications. The Comprehensive Cardiomyopathy Panels section explicitly states panels are not reasonable and necessary for indications beyond the stated criteria, and professional guidance favors phenotype-targeted panels.

    Multiple arrhythmia and cardiomyopathy sections reiterate that genetic panel testing is limited to the clinical situations described and that panel testing is not reasonable and necessary for other indications. The Comprehensive Arrhythmia Panels and Dilated Cardiomyopathy Panels sections both state panels are not reasonable and necessary outside the listed diagnostic criteria.

    The policy discourages use of hypothesis-free genetic testing: large unfocused panels, whole-exome, or whole-genome sequencing without a clinical phenotype are not recommended for routine patient care. Such testing may be considered only in a research context and is not supported for routine diagnostic evaluation.

    Before diagnosing Brugada syndrome and proceeding to genetic testing, the policy requires exclusion of Brugada phenocopies: myocardial ischemia, electrolyte disturbances, and drug intoxications should be ruled out per expert consensus statements.

    Medical Policies are used to administer plan benefits but do not themselves authorize services or create contractual coverage. Benefit determination depends on the terms and conditions of the applicable benefit contract; the policy does not constitute authorization, certification, or a contract for benefits.

    Comprehensive cardiomyopathy, arrhythmia, combined cardiomyopathy/arrhythmia, hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM) multigene panels are each covered only when the specific clinical criteria in those sections are met; otherwise, these comprehensive panels are considered not reasonable and necessary. Where indicated, guidelines recommend phenotype-directed (targeted) panels.

    Restrictive cardiomyopathy multigene panel testing is explicitly considered not reasonable and necessary in this policy. For Brugada syndrome, the policy limits diagnostic testing to SCN5A single-gene analysis when criteria are met and states that testing of other Brugada-associated genes or multigene panels is not considered reasonable and necessary.

    The policy advises against routine use of large unfocused gene panels or genomic sequencing in the absence of an identified phenotype or diagnostic suspicion. In line with expert consensus, hypothesis-free genomic testing without a compatible clinical phenotype is discouraged and not recommended for routine patient care.

    For Brugada syndrome the policy notes that only SCN5A currently has strong gene–disease validity and therefore recommends against diagnostic reporting of genes with disputed ClinGen validity. Genetic testing of genes other than SCN5A is not recommended for routine diagnostic use.

    Provider Actions, Authorization, and Documentation Requirements

    Prior Authorization

    Preauthorization required

    Preauthorization is required for MA Specialty Testing: Cardiovascular. When a National Coverage Determination (NCD) or Local Coverage Determination (LCD) exists it will be applied first; when no CMS guideline applies this policy governs preauthorization decisions.

    • Obtain prior authorization before ordering specialty cardiovascular genetic testing.
    • If an NCD/LCD applies, follow that determination first; otherwise follow this policy.
    Prior Authorization

    Preauthorization required for listed panels and single‑gene tests

    Preauthorization must be obtained for the listed cardiovascular multigene panels and single-gene analyses. Requests must document that the member meets the condition‑specific clinical criteria described in this policy.

    • Include clinical findings that satisfy the specific criteria for the panel or single‑gene test (e.g., imaging thresholds, ECG findings, family history).
    • Use the appropriate panel code when a panel is performed.
    Prior Authorization

    Seek prior authorization for phenotype‑focused panels

    Preauthorization should be requested for phenotype‑directed comprehensive cardiomyopathy or arrhythmia panels when guideline‑based indications are present (for example, a clearly affected proband, survivors of SCA, or relatives of SUD/SCD cases).

    • Phenotype‑directed testing is preferred over hypothesis‑free testing.
    • Collect and document phenotype information and, when applicable, autopsy tissue suitable for DNA storage.
    Billing Rule

    Prior authorization required for listed panel codes

    Selected panel and molecular CPT/CPT‑PLA codes listed in the policy (for example 0237U for a cardiac ion channelopathies panel) are subject to the payer's prior authorization processes and must be submitted through the Quick Code Search/code pair tool.

    • Enter the procedure code (e.g., 0237U) when submitting the authorization request.
    • Ensure the panel code used matches the test performed and gene content when required.
    Billing Rule

    Preauthorization required for listed molecular pathology and panel codes

    Preauthorization is required for specialty cardiovascular molecular testing using the CPT/CPT‑PLA and molecular pathology codes listed in the policy (examples include 81413–81414, 81439, 81401, 81407, 0237U). Gene‑panel composition must be documented on the request when specified.

    • Provide the CPT or CPT‑PLA code from the policy when requesting authorization.
    • If the policy specifies gene content for a panel, include gene‑content information on the request (e.g., cardiac ion channelopathies panels must include ANK2, CASQ2, CAV3, KCNE1, KCNE2, KCNH2, KCNJ2, KCNQ1, RYR2, SCN5A).
    Prior Authorization

    Policy within MA Specialty Testing preauthorization program

    This policy is part of the MA Specialty Testing: Cardiovascular preauthorization program; testing for the conditions and codes addressed may require preauthorization as described in this policy.

    • Follow the MA Specialty Testing program procedures when requesting authorization.
    • Policies do not constitute guarantee of payment—benefit terms determine coverage.
    Note

    Provider responsibilities for authorization and counseling

    Providers must follow the policy's preauthorization and documentation requirements when ordering specialty cardiovascular genetic testing.

    • Ensure testing decisions and interpretation involve or consult a cardiac genetics expert.
    • Obtain pre‑test and post‑test genetic counseling when possible.
    Step Therapy

    Brugada testing: SCN5A single‑gene only when criteria met

    For suspected Brugada syndrome, single‑gene analysis of SCN5A is acceptable when the policy criteria are met; testing of other genes or multigene panels for Brugada is explicitly considered not reasonable and necessary.

    • SCN5A testing covered when ECG criteria, exclusion of phenocopies, and clinical features (e.g., syncope, VF, family history) are documented.
    • Do not order multigene Brugada panels or other BrS genes for diagnostic testing per policy.
    Note

    Prefer multigene panels for heterogeneous cardiomyopathies; avoid unfocused testing

    For heterogeneous cardiomyopathies, multigene panels are preferred over serial single‑gene testing; unfocused large panels, whole‑exome, or whole‑genome sequencing without a defined phenotype are discouraged for routine care.

    • Order a phenotype‑directed multigene panel for cardiomyopathy when the member meets diagnostic criteria.
    • Avoid hypothesis‑free or very large unfocused panels unless part of a research effort.
    Step Therapy

    No step therapy required when CPVT or SQTS criteria are met

    When diagnostic criteria for CPVT or SQTS are met (per guideline diagnostic criteria or SQTS diagnostic score), molecular genetic testing is recommended; the policy does not require prior step‑therapy sequencing before testing.

    • If CPVT or SQTS diagnostic criteria are satisfied, proceed with recommended molecular testing.
    • No step‑therapy or prior incremental sequencing steps are specified in the policy.
    Note
    Note
    Documentation Required

    Genetic counseling and cardiac genetics expertise recommended

    Providers should ensure testing requests include genetic counseling involvement and, when appropriate, consultation with cardiac genetics experts for test selection and interpretation.

    • Document that pre‑test and post‑test genetic counseling was provided or offered.
    • Consult a cardiac genetics expert for interpretation when results are complex.
    Billing Rule

    Use correct panel code and document clinical criteria

    If a panel is performed, use the appropriate panel CPT/CPT‑PLA code and document that the member meets the clinical criteria for the requested panel as specified in the policy.

    • Select the panel code that corresponds to the test and include condition‑specific clinical evidence that meets policy criteria.
    • Failure to use the appropriate code and document criteria may delay authorization.
    Documentation Required

    Provide required clinical documentation with requests

    Include detailed clinical documentation with the preauthorization request: phenotype description, personal and family history, ECGs, imaging results, and specimen details if available (for example, autopsy tissue or prior genetic test results).

    • Attach ECG tracings and imaging reports that demonstrate the diagnostic measurements described in the policy (e.g., LV wall thickness, EF, RVOT dimensions).
    • Provide family history and any prior molecular testing results.
    Documentation Required

    SQTS documentation required for authorization

    When requesting SQTS testing, include ECG findings (QTc and J‑point–Tpeak interval), clinical history, family history, and the SQTS diagnostic score elements when available to demonstrate that diagnostic criteria are met.

    • Document baseline ECG without modifiers that shorten QT.
    • Provide calculated SQTS diagnostic score or component elements.
    Documentation Required

    Document Brugada phenotype and exclusion of phenocopies

    For Brugada syndrome testing, document compatible clinical features (e.g., recurrent syncope, ventricular arrhythmia, family history), the EKG pattern (Type 1 or provoked Type 1), and exclusion of phenocopies such as ischemia, electrolyte disturbance, or drug intoxication.

    • Attach ECG demonstrating Type 1 or provoked Type 1 pattern when available.
    • State that phenocopies have been excluded and provide supporting data.
    Billing Rule

    Include panel code and gene‑content on preauthorization

    When submitting preauthorization for cardiac genetic panels include the specified panel CPT/CPT‑PLA codes (for example 0237U) and indicate gene‑content when required (for example cardiac ion channelopathies panels must include at least ANK2, CASQ2, CAV3, KCNE1, KCNE2, KCNH2, KCNJ2, KCNQ1, RYR2, SCN5A).

    • List the exact CPT or CPT‑PLA code used for the test on the authorization request.
    • If policy requires minimum gene content for a panel, include the gene list or laboratory gene content statement.
    Note

    Ensure documentation aligns with benefit terms

    Medical policies reference CPT codes and are used to administer plan benefits; providers should ensure documentation submitted for authorization aligns with the applicable benefit contract and policy guidance.

    • Policies do not guarantee payment — benefits are determined by the member's contract.
    • Ensure submitted documentation matches policy requirements to reduce risk of denial.
    Denial Risk

    NCD/LCDs applied first; missing authorization may trigger denial

    If an NCD or LCD exists it will be applied before this policy; absence of required preauthorization or failure to meet policy criteria may result in denial of the request.

    • Check for applicable NCDs/LCDs prior to submission.
    • Obtain required preauthorization and document clinical criteria to avoid denials.
    Denial Risk

    HCM panel denial trigger — insufficient LVH evidence

    Genetic testing for HCM via multigene panel is not reasonable and necessary for indications other than unexplained LV hypertrophy defined by myocardial wall thickness ≥15 mm in adults (or z‑score ≥2 in children).

    • Provide imaging demonstrating LV wall thickness ≥15 mm (adults) to support medical necessity.
    • Requests for HCM panels outside these criteria are likely to be denied.
    Denial Risk

    DCM panel denial trigger — does not meet DCM criteria

    Genetic testing for DCM via multigene panel is not reasonable and necessary for indications that do not meet the listed DCM criteria, including left ventricular enlargement, systolic dysfunction (EF <50%), and exclusion of non‑genetic causes.

    • Document LV enlargement and EF <50% on imaging and that non‑genetic causes have been ruled out.
    • Requests lacking these elements may be denied.
    Denial Risk

    Arrhythmogenic cardiomyopathy panel denial trigger

    Genetic testing for arrhythmogenic cardiomyopathy via multigene panel is not reasonable and necessary for indications other than the specified Task Force major/minor diagnostic criteria combinations described in the policy.

    • Provide diagnostic Task Force criteria measurements or findings (imaging, ECG, biopsy) when requesting testing.
    • Requests that do not meet Task Force criteria are at risk for denial.
    Denial Risk

    LQTS panel denial trigger — does not meet ECG/Schwartz criteria

    LQTS multigene panel testing is not reasonable and necessary for indications other than the defined ECG/proband criteria or symptomatic presentations with cardiologist suspicion or Schwartz score thresholds; non‑genetic causes must be excluded.

    • Document prolonged QTc by age‑appropriate thresholds (>460 ms prepuberty; >480 ms adults) or cardiologist assessment/Schwartz score ≥3.
    • Exclude reversible causes of QT prolongation in the documentation.
    Denial Risk

    Brugada testing denial trigger — criteria not met

    SCN5A variant analysis for Brugada syndrome (codes 81407, S3861) is not reasonable and necessary for indications other than the specified ECG phenotype, exclusion of phenocopies, and clinical features required by policy.

    • Provide Type 1 (or provoked Type 1) ECG documentation, evidence phenocopies are excluded, and relevant clinical features (e.g., syncope, VF, family history).
    • Requests for SCN5A testing lacking these elements may be denied.
    Denial Risk

    Unfocused panel risk — avoid hypothesis‑free testing without phenotype

    Use of large unfocused gene panels or hypothesis‑free testing (including whole‑exome or whole‑genome sequencing) in the absence of a clinical phenotype is discouraged and not recommended for routine patient care; such unfocused testing may not meet clinical applicability criteria and risk denial.

    • Order phenotype‑directed panels rather than broad unfocused panels when no phenotype is identified.
    • Requests for hypothesis‑free testing may be denied as not medically necessary.
    Billing Rule

    Procedure/diagnosis code pairing required for Quick Code Search

    Enter both a procedure and diagnosis code pair when using the Quick Code Search; absence of an appropriate code pair may prevent automated approval or display of policy guidance and delay authorization.

    • Add the procedure code first, then the diagnosis code when creating a code pair.
    • If the code pair is not present, manual review or additional documentation may be required.
    Denial Risk

    Preauthorization required — lack of authorization may trigger denial

    Preauthorization is required for MA Specialty Testing: Cardiovascular; failure to obtain required preauthorization may lead to denial of the service.

    • Obtain authorization before performing testing covered by this policy.
    • Confirm authorization status through the payer's Quick Code Search tool.
    Note

    Coverage subject to benefit contract terms

    Services are subject to the terms and conditions of the applicable benefit contract; Medical Policies do not constitute authorization or guarantee payment.

    • Verify member benefit coverage and contract terms prior to testing.
    • Policies guide determination of scientific validity but do not replace benefit contract terms.

    CPT, CPT-PLA, and Molecular Pathology Codes

    Reference table codesmixed
    81161Listed in reference table
    81439Listed in reference table
    81413Listed in reference table
    81414Listed in reference table
    0237UGenomic Unity Cardiac Ion Channelopathies Analysis
    81403Listed in reference table
    81406Listed in reference table
    81407Listed in reference table
    81479Listed in reference table
    81401Listed in reference table
    1–10 of 40
    1/4
    Brugada single-gene codes citedCPTCovered
    81407SCN5A variant analysis (single-gene)
    S3861SCN5A variant analysis (single-gene)
    CPT-PLA (listed)CPT-PLA
    0237UCARDIAC ION CHANNELOPATHIES GENOMIC SEQ ALYS PNL
    CPT4 (examples listed)CPT
    81161DMD DUPLICATION/DELETION ANALYSIS
    81193NTRK3 TRANSLOCATION ANALYSIS
    81311NRAS GENE ANALYSIS VARIANTS IN EXON 2&3
    81401MOLECULAR PATHOLOGY PROCEDURE LEVEL 2
    CPT-PLA / Proprietary Panel CodesCPT-PLA
    0237UCARDIAC ION CHANNELOPATHIES GENOMIC SEQ ALYS PNL
    Molecular pathology and panel CPT codesCPT
    81161DMD DUPLICATION/DELETION ANALYSIS
    81193NTRK3 TRANSLOCATION ANALYSIS
    81311NRAS GENE ANALYSIS VARIANTS IN EXON 2&3
    81401MOLECULAR PATHOLOGY PROCEDURE LEVEL 2
    81403MOLECULAR PATHOLOGY PROCEDURE LEVEL 4
    81404MOLECULAR PATHOLOGY PROCEDURE LEVEL 5
    81405MOLECULAR PATHOLOGY PROCEDURE LEVEL 6
    81406MOLECULAR PATHOLOGY PROCEDURE LEVEL 7
    81407MOLECULAR PATHOLOGY PROCEDURE LEVEL 8
    81408MOLECULAR PATHOLOGY PROCEDURE LEVEL 9
    1–10 of 16
    1/2
    Hypertrophic cardiomyopathy LV wall thickness
    Adults>= 15 mm (maximal myocardial wall thickness on echo or CMR)
    Childrenz-score >= 2 (echocardiogram or cardiac MRI)
    Policy actionGenetic testing via multigene panel may be considered when unexplained LVH meets these thresholds; panels not reasonable for other indications
    Dilated cardiomyopathy ejection fraction
    Systolic dysfunction thresholdEjection fraction <50% (by echo, cardiac MRI, or LV angiogram)
    Associated requirementLeft ventricular enlargement must also be present
    ExclusionNon-genetic causes (prior MI, valvular/congenital disease, toxins, thyroid, inflammatory/infectious, severe hypertension, radiation) must be ruled out
    Hypertrophic cardiomyopathy LV wall thickness
    Adult diagnostic cutoff>= 15 mm (maximal end-diastolic LV wall thickness on echo or CMR)
    Pediatric thresholdz-score >= 2 (adjusted for body size; some guidelines use z-score >2.5 for screening in low-pretest settings)
    Clinical noteDiagnosis requires absence of another cause of hypertrophy and imaging confirmation
    Dilated cardiomyopathy systolic dysfunction
    Systolic dysfunctionEjection fraction <50% on echocardiogram, cardiac MRI, or left ventricular angiogram
    Required imagingLeft ventricular enlargement on echo or cardiac MRI must be documented
    Rule-out criteriaNon-genetic causes of DCM must be excluded prior to panel testing
    Arrhythmogenic cardiomyopathy imaging and ECG thresholds
    PLAX RVOT (major)>32 mm (or PLAX/BSA >19 mm/m2)
    PSAX RVOT (major)>36 mm (or PSAX/BSA >21 mm/m2)
    Rao RVEDV/BSA (major)>110 mL/m2 (male) or >100 mL/m2 (female)
    Functional exampleRVEF <40% (major diagnostic threshold)
    Long QT Syndrome QTc thresholds
    Pediatric QTc thresholdQTc >460 ms (prepuberty)
    Adult QTc thresholdQTc >480 ms (adults) on resting ECG or provocative testing
    ContextProlonged QTc must be confirmed and non-genetic causes excluded prior to genetic testing
    Short QT Syndrome QTc thresholds and score
    Diagnostic QTc cutoffQTc <= 330 ms is Class I diagnostic cutoff for SQTS
    SQTS diagnostic scoreScore >=4 points indicates high-probability SQTS
    Testing recommendationMolecular testing recommended for definitive genes (KCNH2, KCNQ1) in patients meeting these criteria
    HCM diagnostic wall thickness
    Adult HCM cutoff> 15 mm (maximal end-diastolic wall thickness on imaging)
    Imaging modalitiesDiagnosis by 2D echocardiography or cardiovascular magnetic resonance (CMR)
    Genetic testing rationaleGenetic testing beneficial to identify at-risk family members (cascade testing)
    LQTS Schwartz score thresholds
    High-probability Schwartz score>= 3.5 points = high probability of LQTS
    Intermediate probability1.5–3.0 points = intermediate probability
    Testing threshold suggestionUse Schwartz score >=3.0 for selecting patients for molecular screening per guideline commentary
    SQTS QTc diagnostic cutoff
    SQTS QTc diagnostic cutoffQTc <= 330 ms is diagnostic cutoff (HRS/EHRA/APHRS 2013 consensus)
    High-probability scoreSQTS diagnostic score >=4 points indicates high probability
    Testing genesDefinitive genes include KCNH2 and KCNQ1; consider KCNJ2 and SLC4A3 in high-probability index cases
    ARVC imaging/functional thresholds
    RVEF thresholdRVEF <40% (major ARVC diagnostic threshold)
    RVEDV/BSA>110 mL/m2 (male) or >100 mL/m2 (female) (major MRI threshold)
    PLAX RVOT>32 mm (major echo threshold)
    Short QT diagnostic QTc cutoff
    Diagnostic QTc cutoffQTc <= 330 ms is diagnostic cutoff for SQTS
    Clinical scoringUse SQTS diagnostic score alongside QTc and ECG features to determine probability
    Guideline sourceHRS/EHRA/APHRS 2013 consensus statement
    SQTS diagnostic score threshold
    High-probability thresholdSQTS diagnostic score >= 4 points = high-probability
    Intermediate/lowScore 3 = intermediate; <=2 = low probability
    Scoring componentsPoints from QTc strata, J-point–Tpeak interval, clinical history, family history, and genotype
    FH LDL-C thresholds for testing
    ChildrenPersistent LDL-C >160 mg/dL (two or more measurements after intensive lifestyle modification)
    AdultsPersistent LDL-C >190 mg/dL (two or more measurements after intensive lifestyle modification)
    Testing contentFH testing should include at minimum LDLR, APOB, and PCSK9; consider expanded panels for phenocopies

    Background and Scope

    This policy addresses genetic and specialty testing for both inherited and sporadic cardiovascular conditions, including structural cardiomyopathies and electrical (arrhythmic) disorders. It defines covered indications, documentation and preauthorization requirements, and emphasizes that testing decisions and interpretation should involve cardiac genetics expertise and genetic counseling.

    Key Definitions and Panel Content Requirements

    Genetic counseling
    DefinitionPre-test and post-test counseling that facilitates informed decision-making, addresses possibility of incidental findings, and defines a plan for returning results
    RoleStrongly advised before testing; testing and interpretation should involve or consult a cardiac genetics expert
    PurposeHelps manage incidental findings and supports informed consent and result communication
    Close relatives
    First-degree relativesParents, siblings, and children
    Second-degree relativesGrandparents, aunts/uncles, nieces/nephews, grandchildren, half-siblings
    Third-degree relativesGreat grandparents, great aunts/uncles, great grandchildren, first cousins
    Phenocopy
    DefinitionA trait or disease resembling the trait expressed by a genotype but occurring in an individual who is not a carrier of that genotype
    Clinical implicationPhenocopies should be considered and excluded when diagnosing inherited conditions
    Example contextsBrugada phenocopies (ischemia, electrolyte disturbance, drugs) must be excluded
    Premature CAD
    DefinitionPremature coronary artery disease: male subjects <=55 years, female subjects <=65 years
    SourceAdapted from AHA HeFH phenotype definition
    UseUsed in FH testing criteria to define family history of premature CAD
    Sudden cardiac arrest / death
    Sudden cardiac arrest (SCA)Abrupt cessation of cardiac activity with unresponsiveness, absent breathing and signs of circulation; may be reversed by CPR/defibrillation
    Sudden cardiac death (SCD)Death due to cardiovascular cause occurring within one hour of symptom onset
    Sudden unexplained death (SUD)Sudden death in an apparently healthy individual within one hour with no apparent reason
    Close relatives (definition)
    Close relatives (duplicate)First-, second-, and third-degree blood relatives (parents, siblings, children; grandparents, aunts/uncles; great grandparents, first cousins)
    PurposeUsed throughout policy to define familial testing and cascade screening eligibility
    NoteSame definition reproduced for clarity
    Phenocopy (definition)
    Phenocopy (duplicate)A trait/disease resembling a genotype-expressed trait in an individual who is not a carrier
    ImplicationImportant to exclude phenocopies before genetic testing (eg, Brugada)
    Clinical noteConsider differential diagnoses and reversible causes first
    Premature coronary artery disease (CAD)
    Definition (duplicate)Premature CAD: male <=55 years, female <=65 years (AHA HeFH adaptation)
    ContextUsed to assess FH testing candidacy and family history relevance
    SourceSturm et al./AHA definition
    Sudden cardiac arrest / death / unexplained death
    SCA/SCD/SUD definitionsSCA: reversible abrupt cessation of cardiac activity; SCD: death within one hour of symptom onset due to cardiac cause; SUD: unexplained sudden death in an apparently healthy individual
    UseDefinitions applied when evaluating family history and autopsy findings for testing eligibility
    DocumentationAutopsy tissue should be collected/stored for DNA when SUD/SCD occurs
    Short QT syndrome (SQTS) diagnostic QTc cutoff
    Diagnostic QTc cutoffA QTc <= 330 ms is the Class I diagnostic cutoff per HRS/EHRA/APHRS 2013 consensus
    Guideline sourcePriori et al., HRS/EHRA/APHRS 2013
    Policy useUsed to determine eligibility for SQTS genetic testing
    SQTS diagnostic score
    Score descriptionPoint-based diagnostic score assigning points for QTc strata, J-point–Tpeak interval, clinical history, family history, and genotype
    High-probability thresholdTotal score >=4 points indicates high probability of SQTS
    Clinical applicationScore used to select index patients for molecular testing and cascade testing
    Brugada type 1 EKG
    Type 1 EKG definitionCoved ST elevation >=2 mm in V1–V3 with negative T wave (coved morphology), with or without sodium channel blocker challenge
    Type 2/3Saddleback or lesser ST elevation patterns that may convert to Type 1 with provocation
    UseEKG morphology required as part of Brugada diagnostic criteria prior to genetic testing
    Cardiac ion channelopathies genomic sequence analysis panel (81413 / 0237U)
    Panel definitionCardiac ion channelopathies genomic sequence analysis panel (81413 / 0237U) must include sequencing of at least 10 genes
    Example genesShould include ANK2, CASQ2, CAV3, KCNE1, KCNE2, KCNH2, KCNJ2, KCNQ1, RYR2, and SCN5A
    Associated code0237U / 81413 referenced for channelopathy panels
    Aortic dysfunction/dilation genomic sequence analysis (81410)
    Panel requirementAortic dysfunction/dilation genomic sequence analysis (81410) must include sequencing of at least 9 genes
    Example genesExamples include FBN1, TGFBR1, TGFBR2, COL3A1, MYH11, ACTA2, SLC2A10, SMAD3, and MYLK
    Associated code81410 referenced for aortic disease panels
    References
    ContentCitations of expert consensus statements and scientific statements relevant to genetic testing for inherited cardiovascular diseases (eg, HRS/EHRA, AHA, ACMG)
    ExamplesReferences include HRS/EHRA consensus, AHA scientific statement, GeneReviews, and guideline publications cited in policy
    PurposeSupports condition-specific diagnostic thresholds and testing recommendations in the policy

    Policy Revision History

    2026-05-01policy_effectiveLatest

    Policy M.88 (MA Specialty Testing: Cardiovascular) became effective for Blue Cross Blue Shield - Nebraska; establishes criteria, preauthorization requirements, and coding guidance for cardiovascular genetic and specialty testing.

    2027-01-01next_review

    Scheduled next policy review date per document metadata.

    2026copyright

    Document copyright year noted in policy materials.